Dr. Brentjens on CD19-Targeted T Cells in CLL and ALL
2 意见
• 07/14/23
0
0
嵌入
Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, discusses clinical responses in patients with chronic lymphoblastic leukemia (CLL) or acute lymphoblastic leukemia (ALL) following infusion with CD19-Targeted T Cells.
显示更多
脸书评论
SORT BY-
热门评论
-
最新评论